Mirna Therapeutics, Inc. is listed today as Synlogic, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
Funding rounds of Mirna Therapeutics, Inc.| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|
| Jun 2019 | $80 M | Private placement after listing | $50 to $250 million | | equity, options | SEC |
| Mar 2015 | $42 M | No. 3 | $10 to $50 million | | equity | SEC |
| Oct 2012 | $17 M | No. 2 | $10 to $50 million | | equity | SEC |
| Aug 2011 | $2 M | No. 1 | Under $2 million | | equity | SEC |
What its filings and its own website say, sentence by sentence, each with its source.
Mirna Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).
SEC Form D · Jun 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2019
No products or services of Mirna Therapeutics, Inc. are on record.
7 named in official filings. Open an investor to see everything it has backed.
Investors in Mirna Therapeutics, Inc.| Investor | Kind | Amount | Round | Role | Source |
|---|
| Matthew Winkler | Person | not stated | not stated | Held Series A, B, C and D preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Nea 14 GP, LTD | Company | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| NEA Partners 14, L.P. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| New Enterprise Associates 14, L.P. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Pfizer Inc | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Sofinnova Management VIII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Sofinnova Venture Partners VIII, L.P. | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Largest shareholders today
Institutions holding Synlogic, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Mirna Therapeutics, Inc.| Name | Role | Named in |
|---|
| Aoife Brennan | Executive officer | Jun 2019 |
| Todd Shegog | Executive officer | Jun 2019 |
| Casi DeYoung | Executive officer | May 2015 |
| Jon Irvin | Executive officer | May 2015 |
| Paul Lammers | Executive officer | May 2015 |
| Sinil Kim | Executive officer | May 2015 |
| Ana V Ward | Executive officer | Nov 2012 |
| Lynne V Hohlfeld | Executive officer | Nov 2012 |
| Ana C Ward | Executive officer | Aug 2011 |
| Lynne S Hohlfeld | Executive officer | Aug 2011 |
| Aoife Brennan | Director | Jun 2019 |
| Chau Khuong | Director | Jun 2019 |
| Edward Mathers | Director | Jun 2019 |
| Michael Powell | Director | Jun 2019 |
| Nick Leschly | Director | Jun 2019 |
| Patricia Hurter | Director | Jun 2019 |
| Peter Barrett | Director | Jun 2019 |
| Richard P. Shea | Director | Jun 2019 |
| Clay Siegall | Director | May 2015 |
| Corey Goodman | Director | May 2015 |
| Ed Mathers | Director | May 2015 |
| Elaine Jones | Director | May 2015 |
| Larry Alleva | Director | May 2015 |
| Matthew Winkler | Director | May 2015 |
| Paul Lammers | Director | May 2015 |
| Corey V Goodman | Director | Nov 2012 |
| Edward V Mathers | Director | Nov 2012 |
| Elaine V Jones | Director | Nov 2012 |
| Matthew M Winkler | Director | Nov 2012 |
| Michael M Powell | Director | Nov 2012 |
| Christopher D Earl | Director | Aug 2011 |
| Corey S Goodman | Director | Aug 2011 |
| Evan S Melrose | Director | Aug 2011 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.